A bispecific antibody targeting PD-L1/TNFR2 increases tumor targeting and enhances antitumor efficacy in colorectal cancer
These findings support ATAPL1 as a promising dual-targeted therapeutic strategy for CRC. It offers the potential to overcome immune and chemotherapy resistance, reduce off-target effects, and improve treatment outcomes through enhanced immune activation and tumor targeting.
Authors
- Mengdi Wu
- Xiao-Zhen Kang (ORCID: https://orcid.org/0009-0006-2838-3025)
- Yifeng Han (ORCID: https://orcid.org/0000-0002-6247-0708)
- C. F. Xu (ORCID: https://orcid.org/0000-0001-8831-3607)
- Jiwu Wei (ORCID: https://orcid.org/0000-0002-0883-1824)
- Yuxin Li (ORCID: https://orcid.org/0000-0001-9739-9860)
- Qian Peng (ORCID: https://orcid.org/0000-0002-2662-3412)
Institutions
- Nanjing Drum Tower Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1136/jitc-2025-013001
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- National Natural Science Foundation of China
- State Key Laboratory of Pharmaceutical Biotechnology